{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:26:35Z","timestamp":1764433595778,"version":"build-2065373602"},"reference-count":35,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,10,15]]},"DOI":"10.2169\/internalmedicine.5288-25","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T18:09:51Z","timestamp":1744394991000},"page":"2944-2952","source":"Crossref","is-referenced-by-count":1,"title":["Intravenous Verapamil for the Management of Atrial Fibrillation: The Gap Between the Guidelines and Clinical Practice"],"prefix":"10.2169","volume":"64","author":[{"given":"Yuichi","family":"Baba","sequence":"first","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Kawada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kochi Medical School Hospital, Japan"},{"name":"Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Ochi","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Hirota","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohito","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kitaoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37: 2893-2962, 2016.","DOI":"10.5603\/KP.2016.0172"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 83: 52-60, 1991.","DOI":"10.1161\/01.CIR.83.1.52"},{"key":"3","unstructured":"3. Packer M, Kessler PD, Lee WH. Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far. Circulation 75 (6 Pt 2): V56-V64, 1987."},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. January CT, Wann LS, Alpert JS, et al.; ACC\/AHA Task Force Members. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130: e199-e267, 2014.","DOI":"10.1161\/CIR.0000000000000041"},{"key":"5","unstructured":"5. Tsutsui H, Isobe M, Ito H, et al.; Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS 2017\/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure - Digest Version. Circ J 83: 2084-2184, 2019."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 140: e125-e151, 2019.","DOI":"10.1161\/CIR.0000000000000665"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 74: 104-132, 2019.","DOI":"10.1016\/j.jacc.2019.01.011"},{"key":"8","unstructured":"8. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42: 3599-3726, 2021."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tsutsui H, Ide T, Ito H, et al.; Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS\/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Circ J 85: 2252-2291, 2021.","DOI":"10.1253\/circj.CJ-21-0431"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Matsue Y, Damman K, Voors AA, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol 69: 3042-3051, 2017.","DOI":"10.1016\/j.jacc.2017.04.042"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. Lancet 388: 818-828, 2016.","DOI":"10.1016\/S0140-6736(16)31258-2"},{"key":"12","unstructured":"12. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 30: 303-371, 2017."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 23: 352-380, 2021.","DOI":"10.1002\/ejhf.2115"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nagai R, Kinugawa K, Inoue H, et al.; J-Land Investigators. Urgent management of rapid heart rate in patients with atrial fibrillation\/flutter and left ventricular dysfunction: comparison of the ultra-short-acting \u03b21-selective blocker landiolol with digoxin (J-Land Study). Circ J 77: 908-916, 2013.","DOI":"10.1253\/circj.CJ-12-1618"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Horiuchi D, Sasaki S, Kinjo T, et al. Rhythm and rate control effects of intravenous amiodarone for atrial fibrillation complicated by acutely decompensated heart failure. J Arrhythm 30: 167-172, 2014.","DOI":"10.1016\/j.joa.2013.09.005"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Packer M. Calcium channel blockers in chronic heart failure. The risks of &quot;physiologically rational&quot; therapy. Circulation 82: 2254-2257, 1990.","DOI":"10.1161\/01.CIR.82.6.2254"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 319: 385-392, 1988.","DOI":"10.1056\/NEJM198808183190701"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Daoud EG, Weiss R, Bahu M, et al. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 78: 1433-1436, 1996.","DOI":"10.1016\/S0002-9149(97)89297-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kerr AJ, Williams MJ, Stewart RA. Ventricular rate and beat-to-beat variation of stroke volume in atrial fibrillation. Am J Cardiol 87: 1116-1119, 2001.","DOI":"10.1016\/S0002-9149(01)01475-8"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133: 484-492, 2016.","DOI":"10.1161\/CIRCULATIONAHA.115.018614"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Chew CY, Hecht HS, Collett JT, McAllister RG, Singh BN. Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am J Cardiol 47: 917-922, 1981.","DOI":"10.1016\/0002-9149(81)90194-6"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Singh BN, Ellrodt G, Peter CT. Verapamil: a review of its pharmacological properties and therapeutic use. Drugs 15: 169-197, 1978.","DOI":"10.2165\/00003495-197815030-00001"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Yu HT, Yang PS, Lee H, et al. Outcomes of rate-control treatment in patients with atrial fibrillation and heart failure - a nationwide cohort study. Circ J 82: 652-658, 2018.","DOI":"10.1253\/circj.CJ-17-0669"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Elkayam U. Calcium channel blockers in heart failure. Cardiology 89 (Suppl 1): 38-46, 1998.","DOI":"10.1159\/000047278"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Katz S. Safety of calcium antagonists in patients with congestive heart failure. Clin Ther 19 (Suppl A): 92-113, 1997.","DOI":"10.1016\/S0149-2918(97)80039-2"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Walsh RW, Porter CB, Starling MR, O&apos;Rourke RA. Beneficial hemodynamic effects of intravenous and oral diltiazem in severe congestive heart failure. J Am Coll Cardiol 3: 1044-1050, 1984.","DOI":"10.1016\/S0735-1097(84)80365-4"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Heywood JT, Graham B, Marais GE, Jutzy KR. Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure. Am J Cardiol 67: 1150-1152, 1991.","DOI":"10.1016\/0002-9149(91)90885-O"},{"key":"28","unstructured":"28. Heywood JT. Calcium channel blockers for heart rate control in atrial fibrillation complicated by congestive heart failure. Can J Cardiol 11: 823-826, 1995."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Lundstr\u00f6m T, Ryd\u00e9n L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 16: 86-90, 1990.","DOI":"10.1016\/0735-1097(90)90461-W"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Ulimoen SR, Enger S, Pripp AH, et al. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J 35: 517-524, 2014.","DOI":"10.1093\/eurheartj\/eht429"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Atwood JE, Sullivan M, Forbes S, et al. Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol 10: 314-320, 1987.","DOI":"10.1016\/S0735-1097(87)80013-X"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Pinter A, Dorian P, Paquette M, et al. Left ventricular performance during acute rate control in atrial fibrillation: the importance of heart rate and agent used. J Cardiovasc Pharmacol Ther 8: 17-24, 2003.","DOI":"10.1177\/107424840300800i104"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 29: 1149-1153, 2001.","DOI":"10.1097\/00003246-200106000-00011"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. B\u00f6hm M, Schwinger RH, Erdmann E. Different cardiodepressant potency of various calcium antagonists in human myocardium. Am J Cardiol 65: 1039-1041, 1990.","DOI":"10.1016\/0002-9149(90)91013-V"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Yamashita T, Nakasu Y, Mizutani H, Sumitani K. Mid-term prognosis after landiolol treatment in atrial fibrillation\/atrial flutter patients with chronic heart failure - a prospective observational survey (AF-CHF Landiolol Survey) -. Circ Rep 3: 34-43, 2020.","DOI":"10.1253\/circrep.CR-20-0119"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_5288-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:27:37Z","timestamp":1760761657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_5288-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":35,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5288-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"5288-25"}}